EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY-NC 4.0

Third-line treatment decision-making for metastatic colorectal cancer: a cross-sectional survey of US community physicians

Christopher Cann iD, Sophia Zhao, Nadeem Khan, Malinda O'Donnell iD, Melina Taylor, Tehseen Salimi

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag018 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift The Oncologist, 2026. Verfasst von Christopher Cann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taiho Oncology Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide, with increasing incidence in the US. Improvements in disease management and the increasing incidence of patients with metastatic CRC (mCRC) at younger ages has resulted in more patients being treated in the third-line setting. Treatment has evolved beyond chemotherapy with the approval of newer agents, but there is no consensus on the optimized choice or sequencing post second-line treatment. Identification of the drivers of treatment decisions may provide evidence to guide decision-making, ensuring that patients receive optimal care. The objective of this study was to evaluate treatment preferences and prescribing patterns for third-line mCRC among community-based physicians.

Methods

This study surveyed community-based physicians in the US who were actively treating patients with mCRC.

Results

Overall survival (OS) and impacts to patient quality of life (QoL) were primary considerations for any third-line treatment for mCRC. Physicians considered OS and progression-free survival (PFS) as extremely important factors when making third-line treatment decisions. Most physicians selected trifluridine-tipiracil (FTD-TPI) combined with bevacizumab as their first treatment choice for third-line mCRC (60%), compared to regorafenib (12%), FTD-TPI monotherapy (8%), capecitabine (8%), and fruquintinib (6%). Physicians identified fatigue, neutropenia, and hand-foot syndrome as the most challenging adverse events (AEs) to manage, while hand-foot syndrome and allergic reactions were AEs that would most likely lead physicians to discontinue treatment.

Conclusion

These findings highlight the third-line treatment preferences and prescribing patterns of community-based physicians who are actively treating patients with mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansCross-Sectional StudiesMaleFemaleUnited StatesThymineMiddle AgedTrifluridineDrug CombinationsNeoplasm MetastasisPhysiciansPyrrolidinesPyridinesPractice Patterns, Physicians'BevacizumabQuality of LifeSurveys and QuestionnairesPhenylurea CompoundsClinical Decision-Making

Stichwörter der Autor:innen

fruquintinibmetastatic colorectal cancerphysician preferenceprescribing patternsregorafenibtrifluridine-tipiracil

Substanzen

Thyminetrifluridine tipiracil drug combinationTrifluridineDrug CombinationsPyrrolidinesPyridinesBevacizumabregorafenibPhenylurea Compounds

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States.
  • Medical Affairs, Taiho Oncology, Inc, Princeton, NJ 08540, United States.
  • Clinical Research Group, Thermo Fisher Scientific, Waltham, MA 02451, United States.

ORCID-Profile: Christopher Cann, Malinda O'Donnell

Förderung

  • Taiho Oncology Inc.

Zitieren

APA

Cann, C., Zhao, S., Khan, N., O'Donnell, M., Taylor, M., & Salimi, T. (2026). Third-line treatment decision-making for metastatic colorectal cancer: a cross-sectional survey of US community physicians. The Oncologist. https://doi.org/10.1093/oncolo/oyag018

Vancouver

Cann C, Zhao S, Khan N, O'Donnell M, Taylor M, Salimi T. Third-line treatment decision-making for metastatic colorectal cancer: a cross-sectional survey of US community physicians. The Oncologist. 2026. doi:10.1093/oncolo/oyag018

BibTeX
@article{Cann2026,
  author = {Cann, Christopher and Zhao, Sophia and Khan, Nadeem and O'Donnell, Malinda and Taylor, Melina and Salimi, Tehseen},
  title = {Third-line treatment decision-making for metastatic colorectal cancer: a cross-sectional survey of US community physicians},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag018}
}
Kostenlos starten →